捷強裝備(300875.SZ):股東姚驊完成減持1.9695%股份
格隆匯4月7日丨捷強裝備(300875.SZ)公佈,公司近日收到股東姚驊出具的《關於減持計劃期限屆滿暨實施完畢的吿知函》,截至2022年4月3日,姚驊披露的減持計劃期限已屆滿,累計減持151.25萬股,全部通過大宗交易方式減持,佔公司總股本的1.9695%。
該次減持後,姚驊持有公司股份15萬股,佔公司股份總數0.1953%。截至2022年4月7日,該次減持計劃剩餘股份不再交易,該次減持計劃實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.